<DOC>
	<DOCNO>NCT00927394</DOCNO>
	<brief_summary>The purpose study evaluate blood pressure ( BP ) -lowering efficacy combination aliskiren valsartan , initial therapy , compare valsartan monotherapy Type II Diabetic patient Stage II hypertension .</brief_summary>
	<brief_title>Aliskiren Valsartan v Valsartan Alone Patients With Stage II Systolic Hypertension Type II Diabetes Mellitus</brief_title>
	<detailed_description>When protocol Amendment 2 release , patient already randomize study . These patient include trial prior make change eligibility criterion . Thus , study contains 2 distinct cohort . Cohort 1 contain patient already randomize , deem eligible base original inclusion/exclusion criterion , prior Amendment 2 . No new patient randomize Cohort 1 . Cohort 2 contains patient randomize , find eligible base revise inclusion/exclusion criterion , Amendment 2 . Differences inclusion exclusion criterion indicate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients eligible able participate study , give write informed consent assessment perform . Men woman 18 year old . Patients Type 2 diabetes mellitus HbA1c ≤ 9 % visit 1 stable antidiabetic regimen include insulin stable diet exercise least 4 week prior visit 1 . Cohort 1 : Patients Stage 2 systolic hypertension , define MSSBP ≥160 mmHg &lt; 200 mmHg Visit 5 ( randomization ) . Patients newly diagnose hypertension receive antihypertensive medication least 4 week ( 28 day ) prior Visit 1 must MSSBP ≥ 160 mmHg &lt; 200 mmHg Visit 1 , otherwise , consider screen failure . Patients receive antihypertensive medication must MSSBP ≥150 mmHg &lt; 200 mmHg Study Visit 1 , otherwise consider screen failure . Cohort 2 : Patients must also mean 8hour daytime ambulatory systolic blood pressure ( ASBP ) ≥140 mmHg AND mean 8hour daytime ambulatory diastolic blood pressure ( ADBP ) ≥90 mmHg Visit 5 ( randomization ) . Hypertensive patient MSSBP ≥150 mmHg &lt; 200 mmHg AND MSDBP ≥95 &lt; 120 mmHg Visit 5 ( randomization ) . Patients newly diagnose hypertension receive antihypertensive medication least 4 week ( 28 day ) prior Visit 1 must MSSBP ≥150 mmHg &lt; 200 mmHg MSDBP ≥95 &lt; 120 mmHg Visit 1 , otherwise , consider screen failure . Office blood pressure measure cuff ( MSSBP ≥200 mmHg MSDBP ≥120 mmHg ) . History evidence secondary hypertension etiology . Refractory hypertension , define uncontrolled BP ( ≥140/90 mmHg ) receive 3 antihypertensive medication maximum approve dose drug , one must diuretic . Patients treat 3 antihypertensive medication ( component combination drug count individually ) . Type 2 diabetes mellitus currently require insulin treatment . modification diet renal disease ( MDRD ) estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m2 Serum sodium less low limit normal , serum potassium &lt; 3.5 mEq/L ≥ 5.3 mEq/L Visit 1 . Known KeithWagener grade III IV hypertensive retinopathy . Cohort 1 : Patients know diabetic retinopathy ( eg , history laser therapy diabetic retinopathy ) diabetic neuropathy ( eg , receive medication diabetic neuropathy ) . Cohort 2 : Patients know diabetic retinopathy diabetic neuropathy and/or history treatment either . Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hypertension , Type II Diabetes , Aliskiren , Valsartan ,</keyword>
	<keyword>Systolic blood pressure , Diastolic blood pressure ,</keyword>
	<keyword>Stage II , Combination</keyword>
</DOC>